Isabella Ciccone, MPH

In the phase 3 OPTIMUM study of ponesimod, findings showed that MRI features in patients with multiple sclerosis were significantly associated with clinical scales.

Robert Glanzman, MD, the chief medical officer at the ImmunoBrain Checkpoint, talked about IBC-Ab002 as a promising anti-PD-L1 monoclonal antibody to improve cognition in patients with Alzheimer disease.

Vera Bril, MD, FRCPC, lead investigator of the MycarinG study, shared her reactions to recent approval of rozanolixizumab-noli, the first approved therapy for both subtypes of generalized myasthenia gravis in adults.

Reasons behind the CRL were not related to efficacy and do not impact Amneal’s 2023 financial guidance, which did not include IPX203 revenues.

A group of experts in the care of patients with neurological conditions—Amynah Pradhan, PhD; Katherine Podraza, MD, PhD; Elizabeth K. Seng, PhD; Olivia Begasse de Dhaem, MD, FAHS; Sait Ashina, MD, FAHS—shared their perspectives on hot topics of treatment and management in headache/migraine from the 2023 American Headache Society Annual Scientific Meeting.

A group of experts in the care of patients with neurological conditions—Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath; Andrew Solomon, MD; Anne H. Cross, MD; Anthony Feinstein, MPhil, PhD, FRCP; Brian G. Weinshenker, MD, FRCP—shared their perspectives on hot topics of treatment and management in multiple sclerosis from the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting.

As a recap from AHS 2023, get caught up on some of the latest news in neurology as the NeurologyLive® team shares some of our data updates.

John DeLuca, PhD, senior vice president for Research and Training at Kessler Foundation, discussed the challenges in understanding and measuring fatigue in patients with multiple sclerosis.

As a recap from CMSC 2023, get caught up on some of the latest news in neurology as the NeurologyLive® team shares some of our data updates.

As part of our monthly clinician spotlight, NeurologyLive® highlighted migraine expert Jason J. Sico, MD, MHS, national director of the Headache Centers of Excellence program within the Veterans Health Administration.

In patients with early Parkinson disease, results showed that UB-312 was generally safe and well-tolerated, which supports the advancement of the vaccine into further clinical development.

In honor of Dravet Syndrome Awareness Day, held June 23, 2023, get caught up on some of the latest news in Dravet syndrome as the NeurologyLive® team shares some of our data updates.

B U. K. Li, MD, emeritus professor of pediatrics and gastroenterology at the Medical College of Wisconsin, highlights the significant overlap between cyclic vomiting syndrome, abdominal migraine, and migraine headaches.

Over an 8-week period, patients with migraine and major depressive disorder who were treated with fremanezumab showed significant reductions in HAMD-17 and PHQ-9 scores.

Garth T. Whiteside, PhD, head of preclinical development at Imbrium Therapeutics, discussed a phase 2 clinical study that explored the use of sunobinop in patients with insomnia during recovery from alcohol use disorder.

Following the initiation or switch to a new migraine preventive medication, patients taking galcanezumab showed numerically greater 3-month improvements for most measures of health-related quality of life and disability.

The combination of both REN and gepants for acute migraine treatment may have an increased efficacy compared with REN alone, an expected result based on the different actions of the treatments.

The use of intravenous ketamine in pediatric patients with refractory headaches resulted in a median pain reduction of 50% at discharge and nearly two-third of patients did not need further rescue therapies 1 month posttreatment.

Elizabeth K. Seng, PhD, associate professor at Yeshiva University and Albert Einstein College of Medicine, talked about migraine management through the lens of behavioral factors that clinicians can recommend and encourage to their patients.

Allison Verhaak, PhD, a clinical psychologist from Ayer Neuroscience Institute at Hartford Healthcare Headache Center, discussed focus group and survey data on themes in migraine-related stigma, and the importance of creating a migraine specific stigma scale.

A retrospective cohort study observed no significant difference in the number of patients who discontinued concurrent peripheral nerve blocks and onabotulinumtoxinA, which the authors recognized as a marker of clinical relevance.

Investigators concluded that the increased prevalence of medication-overuse headache might be because of the lack of understanding about the condition in both providers and patients with migraine.

Findings from a subgroup analysis investigating kinetic oscillation stimulation showed that the treatment potential might be an effective and safe option for preventing chronic migraine.

Patients with Parkinson disease who were inpatients had significant impacts on their length of stay, readmissions, and morbidity after hospitalization when administered contraindicated medications.

In a recent survey, a group of advanced practice providers recognized the importance and considered the emotional impact of the unexpected return of symptoms on the life of a patient with Parkinson disease.

Results from the phase 3 LAVENDER trial investigating trofinetide (Daybue; Acadia), which supported the first FDA-approved treatment for Rett syndrome, were recently published in Nature Medicine.

Over a 5-year period in a study, both insomnia protective and risk factors in adults were observed as significantly associated with the sleep disorder, offering valuable insights for prevention strategies.

The FDA is set to make a final decision in July 2023, and if approved, lecanemab would join aducanumab as the only antiamyloid therapies available to treat early-stage Alzheimer disease.

Patients given slow oscillatory transcranial direct current stimulation during sleep recalled significantly more words 2 hours post-awakening compared with the sham group.

Preclinical findings show the potential of samelisant, a potent and orally active Histamine H3 receptor inverse agonist, as a potential treatment for patients with Parkinson disease who experience excessive daytime sleepiness.